Drug repurposing against COVID-19 by GWAS
Health Biotechnology and Biopharma
; 4(1):1-6, 2021.
Artículo
en Inglés
| EMBASE | ID: covidwho-2290647
ABSTRACT
This note is prepared by the authors of a recent publication on shared genetic architecture of drug response based on summary statistics from genome-wide association studies (GWAS) to propose a drug repurposing approach for the treatment of coronavirus COVID-19. The authors proposed that in silico studies may be preceded by analyzing shared genetic architecture of drug response based on existing GWAS.Copyright © 2020, Health Biotechnology and Biopharma.
covid-19; drug responsing; genome-wide association studies; in silico; article; computer model; coronavirus disease 2019; drug repositioning; drug response; drug sensitivity; genome-wide association study; human; priority journal; single nucleotide polymorphism; atazanavir; chloroquine; dolutegravir; efavirenz; hydroxychloroquine; lopinavir plus ritonavir; remdesivir; rifampicin; ritonavir
Texto completo:
Disponible
Colección:
Bases de datos de organismos internacionales
Base de datos:
EMBASE
Idioma:
Inglés
Revista:
Health Biotechnology and Biopharma
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS